J.P. Morgan Report Shows Record $20.2B in Obesity and Diabetes Deals in 2025

Highlights from J.P. Morgan Report

• Total deal value in obesity and diabetes drug R&D partnerships hit a record $20.2 billion in 2025.
• Mergers and acquisitions significantly increased, offsetting declines in IPO activity and venture capital investment.

Market Insights

• The rising deal value reflects the high strategic importance and commercial potential of obesity and diabetes therapeutics.
• With over 1 billion people globally affected by obesity, investment focus remains strong on scalable treatment innovations.

Industry Impact

• This record-setting dealmaking climate may accelerate therapeutic development and market competition.
• Investors and stakeholders watch closely as emerging treatments face real-world scaling challenges.

Source: medcitynews.com